Advertisement
Screener

Arcus Biosciences, Inc. (RCUS) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Arcus Biosciences, Inc. Comprehensive Income

Arcus Biosciences, Inc. (RCUS) reported Comprehensive Income of -$91.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05

  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$91.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$129.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$106.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$135.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$353.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$283.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$300.00M.
  • Arcus Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$273.00M, a 625.00% decline from fiscal 2021.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$91.00M
10-Q · filed 2026-08-05
-$220.00M
10-Q · filed 2026-08-05
-$326.00M
derived: sum of 3 quarters · filed 2026-08-05
-$461.00M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$129.00M
10-Q · filed 2026-05-05
-$235.00M
derived: sum of 2 quarters · filed 2026-05-05
-$370.00M
derived: sum of 3 quarters · filed 2026-05-05
-$370.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$106.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$241.00M
derived: sum of 2 quarters · filed 2026-02-25
-$241.00M
derived: sum of 3 quarters · filed 2026-08-05
-$353.00M
10-K · filed 2026-02-25
2025-09-30-$135.00M
10-Q · filed 2025-10-28
-$135.00M
derived: sum of 2 quarters · filed 2026-08-05
-$247.00M
10-Q · filed 2025-10-28
-$342.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$0.00
10-Q · filed 2026-08-05
-$112.00M
10-Q · filed 2026-08-05
-$207.00M
derived: sum of 3 quarters · filed 2026-08-05
-$297.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$112.00M
10-Q · filed 2026-05-05
-$207.00M
derived: sum of 2 quarters · filed 2026-05-05
-$297.00M
derived: sum of 3 quarters · filed 2026-05-05
-$390.00M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$95.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$185.00M
derived: sum of 2 quarters · filed 2026-02-25
-$278.00M
derived: sum of 3 quarters · filed 2026-02-25
-$283.00M
10-K · filed 2026-02-25
2024-09-30-$90.00M
10-Q · filed 2025-10-28
-$183.00M
derived: sum of 2 quarters · filed 2025-10-28
-$188.00M
10-Q · filed 2025-10-28
-$266.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30-$93.00M
10-Q · filed 2025-08-06
-$98.00M
10-Q · filed 2025-08-06
-$176.00M
derived: sum of 3 quarters · filed 2026-02-25
-$246.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31-$5.00M
10-Q · filed 2025-05-06
-$83.00M
derived: sum of 2 quarters · filed 2026-02-25
-$153.00M
derived: sum of 3 quarters · filed 2026-02-25
-$228.00M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31-$78.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$148.00M
derived: sum of 2 quarters · filed 2026-02-25
-$223.00M
derived: sum of 3 quarters · filed 2026-02-25
-$300.00M
10-K · filed 2026-02-25
2023-09-30-$70.00M
10-Q · filed 2024-11-06
-$145.00M
derived: sum of 2 quarters · filed 2024-11-06
-$222.00M
10-Q · filed 2024-11-06
-$287.00M
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30-$75.00M
10-Q · filed 2024-08-08
-$152.00M
10-Q · filed 2024-08-08
-$217.00M
derived: sum of 3 quarters · filed 2025-02-25
-$284.00M
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31-$77.00M
10-Q · filed 2024-05-08
-$142.00M
derived: sum of 2 quarters · filed 2025-02-25
-$209.00M
derived: sum of 3 quarters · filed 2025-02-25
-$278.00M
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31-$65.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
-$132.00M
derived: sum of 2 quarters · filed 2025-02-25
-$201.00M
derived: sum of 3 quarters · filed 2025-02-25
-$273.00M
10-K · filed 2025-02-25
2022-09-30-$67.00M
10-Q · filed 2023-11-07
-$67.48M
10-Q · filed 2022-11-02
-$136.00M
derived: sum of 2 quarters · filed 2023-11-07
-$208.00M
10-Q · filed 2023-11-07
-$208.08M
10-Q · filed 2022-11-02
$70.67M
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30-$69.00M
10-Q · filed 2023-08-07
-$69.22M
10-Q · filed 2022-08-03
-$141.00M
10-Q · filed 2023-08-07
-$140.61M
10-Q · filed 2022-08-03
$137.67M
derived: sum of 3 quarters · filed 2024-02-21
$59.65M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31-$72.00M
10-Q · filed 2023-05-09
-$71.39M
10-Q · filed 2022-05-09
$206.67M
derived: sum of 2 quarters · filed 2024-02-21
$128.65M
derived: sum of 3 quarters · filed 2024-02-21
$52.64M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$278.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
$200.65M
derived: sum of 2 quarters · filed 2024-02-21
$124.64M
derived: sum of 3 quarters · filed 2024-02-21
$52.00M
10-K · filed 2024-02-21
$51.52M
10-K · filed 2022-02-23
2021-09-30-$78.02M
10-Q · filed 2022-11-02
-$154.03M
derived: sum of 2 quarters · filed 2022-11-02
-$226.67M
10-Q · filed 2022-11-02
-$278.69M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$76.01M
10-Q · filed 2022-08-03
-$148.65M
10-Q · filed 2022-08-03
-$200.66M
derived: sum of 3 quarters · filed 2023-02-28
-$198.91M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$72.64M
10-Q · filed 2022-05-09
-$124.65M
derived: sum of 2 quarters · filed 2023-02-28
-$122.89M
derived: sum of 3 quarters · filed 2023-02-28
-$168.11M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$52.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$50.25M
derived: sum of 2 quarters · filed 2023-02-28
-$95.47M
derived: sum of 3 quarters · filed 2023-02-28
-$123.00M
10-K · filed 2023-02-28
-$122.88M
10-K · filed 2021-02-25
2020-09-30$1.76M
10-Q · filed 2021-11-08
-$43.46M
derived: sum of 2 quarters · filed 2021-11-08
-$70.99M
10-Q · filed 2021-11-08
-$87.58M
derived: sum of 4 quarters · filed 2022-02-23
2020-06-30-$45.22M
10-Q · filed 2021-08-05
-$72.75M
10-Q · filed 2021-08-05
-$89.33M
derived: sum of 3 quarters · filed 2022-02-23
-$111.75M
derived: sum of 4 quarters · filed 2022-02-23
2020-03-31-$27.53M
10-Q · filed 2021-05-05
-$44.12M
derived: sum of 2 quarters · filed 2022-02-23
-$66.53M
derived: sum of 3 quarters · filed 2022-02-23
-$94.53M
derived: sum of 4 quarters · filed 2022-02-23
2019-12-31-$16.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23
-$39.00M
derived: sum of 2 quarters · filed 2022-02-23
-$67.00M
derived: sum of 3 quarters · filed 2022-02-23
-$84.54M
10-K · filed 2022-02-23
2019-09-30-$22.41M
10-Q · filed 2020-11-05
-$50.42M
derived: sum of 2 quarters · filed 2020-11-05
-$67.95M
10-Q · filed 2020-11-05
-$80.25M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30-$28.01M
10-Q · filed 2020-08-06
-$45.54M
10-Q · filed 2020-08-06
-$57.83M
derived: sum of 3 quarters · filed 2021-02-25
-$68.67M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$17.53M
10-Q · filed 2020-05-05
-$29.83M
derived: sum of 2 quarters · filed 2021-02-25
-$40.66M
derived: sum of 3 quarters · filed 2021-02-25
-$54.18M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31-$12.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$23.13M
derived: sum of 2 quarters · filed 2021-02-25
-$36.65M
derived: sum of 3 quarters · filed 2021-02-25
-$49.66M
10-K · filed 2021-02-25
2018-09-30-$10.84M
10-Q · filed 2019-11-05
-$24.36M
derived: sum of 2 quarters · filed 2019-11-05
-$37.37M
10-Q · filed 2019-11-05
-$50.61M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30-$13.52M
10-Q · filed 2019-08-06
-$26.53M
10-Q · filed 2019-08-06
-$39.77M
derived: sum of 3 quarters · filed 2019-08-06
-$62.88M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31-$13.01M
10-Q · filed 2019-05-02
-$26.25M
derived: sum of 2 quarters · filed 2019-05-02
-$49.36M
derived: sum of 3 quarters · filed 2019-05-02
-$58.90M
derived: sum of 4 quarters · filed 2019-05-02
2017-12-31-$13.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05
-$36.35M
derived: sum of 2 quarters · filed 2019-03-05
-$45.89M
derived: sum of 3 quarters · filed 2019-03-05
-$53.10M
10-K · filed 2019-03-05
2017-09-30-$23.11M
10-Q · filed 2018-11-08
-$32.65M
derived: sum of 2 quarters · filed 2018-11-08
-$39.85M
10-Q · filed 2018-11-08
2017-06-30-$9.54M
10-Q · filed 2018-08-06
-$16.75M
10-Q · filed 2018-08-06
2017-03-31-$7.21M
10-Q · filed 2018-05-09
2016-12-31-$18.00M
10-K · filed 2019-03-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36